Format

Send to

Choose Destination
Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):20004-8. doi: 10.1073/pnas.0810899105. Epub 2008 Dec 9.

Phospholipase C{beta}3 in mouse and human dorsal root ganglia and spinal cord is a possible target for treatment of neuropathic pain.

Author information

1
Department of Neuroscience, and Department of Clinical Science and Education, Section of Hand Surgery, Södersjukhuset, Karolinska Institutet, S 171 77 Stockholm, Sweden.

Abstract

Treatment of neuropathic pain is a major clinical problem. This study shows expression of phospholipase ss3 (PLCss3) in mouse and human DRG neurons, mainly in small ones and mostly with a nonpeptidergic phenotype. After spared nerve injury, the pain threshold was strongly reduced, and systemic treatment of such animals with the unselective PLC inhibitor U73122 caused a rapid and long-lasting (48-h) increase in pain threshold. Thus, inhibition of PLC may provide a way to treat neuropathic pain.

PMID:
19066214
PMCID:
PMC2604939
DOI:
10.1073/pnas.0810899105
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center